Lilly says labeling for Zyprexa and Symbyax reflects recent data

Share this article:
Eli Lilly & Co. says updated labeling for its atypical antipsychotics Zyprexa (olanzapine) and Symbyax (olanzapine and fluoxetine HCl) reflects recently completed pooled analyses of clinical trial data in adults and adolescents, information from two non-Eli Lilly studies, and discussions with the FDA.
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Read the complete April 2014 Digital Edition

Read the complete April 2014 Digital Edition

Click the above link to access the complete Digital Edition of the April 2014 issue of MM&M, with all text, charts and pictures.

Antidote: Are e-cigarettes safe?

Antidote: Are e-cigarettes safe?

The pros and cons of e-cigarettes

Combating concept churn

Combating concept churn

There's no cure. But the good news is that prophylaxis is possible.